Naari

What Naari does

Naari is a vertically integrated women's health pharmaceutical company headquartered in Noida, India. Founded in 2007, the company focuses specifically on hormone-related therapeutics, spanning what appears to be the full pharmaceutical value chain — from formulation and manufacturing through distribution. The company employs 101-250 people, placing it in the mid-sized Indian pharma segment. Naari is led by a co-founding team with a dual-CEO governance structure: Gulveen Kochhar serves as Co-Founder & CEO (global remit), Prithi S Kochhar as Co-Founder & CEO-India, and Hermann Osterwald as Co-Founder & Chairman. This separation of India and global leadership suggests deliberate operational segmentation across domestic and international markets.

In February 2020, Naari raised $17.5 million in a funding round led by Ascent Capital, the company's primary disclosed institutional capital infusion. The vertical integration model implies ownership of manufacturing capabilities, regulatory compliance infrastructure, and likely distribution relationships targeting the Indian women's hormonal health market and select export geographies. The dual-CEO structure hints at a deliberate international expansion posture alongside the core India business.

Available data does not disclose specific product formulations, regulatory certifications (e.g., DCGI, WHO-GMP), manufacturing capacity, customer concentration, revenue figures, or R&D pipeline. The company's website (naari.co) was inaccessible beyond a verification page during data collection, limiting visibility into product portfolio depth, therapeutic sub-segments (e.g., contraception, HRT, fertility), and channel mix. The competitive position relative to larger Indian pharma players (e.g., Sun Pharma, Cipla) in the women's health sub-segment cannot be assessed from available data.

Name

Naari

Website

https://naari.co

Company type

Private

Founded year

2007

Headcount range

101–250 employees

Short description

Naari is a vertically integrated Indian pharmaceutical company focused on women's hormonal health, headquartered in Noida and founded in 2007. The firm manufactures and distributes hormone-related therapeutics across domestic and international markets, employing 101-250 people.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Gender-Affirming Endocrine Care (HLAKADAM)

Keywords

• Women's health pharmaceuticals
• Hormonal therapeutics
• Gynecological treatments
• Hormone replacement therapy
• Reproductive health drugs

Headquarters

HQ city

Noida

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Naari is a vertically integrated women's health pharmaceutical business focused on hormone-based products. The company develops, manufactures, and distributes therapeutics targeting women's hormonal, gynecological, and reproductive health needs. Its operations span formulation through to distribution of hormone-related pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Products and services

• Women's Health Pharmaceutical Portfolio (Hormone-based therapeutics) Portfolio of hormone-based pharmaceutical products targeting women's hormonal, gynecological, and reproductive health indications, including menopausal and related therapeutic areas. Sold to healthcare intermediaries — distributors, hospitals, clinics, and pharmacies — for dispensing to patients.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Mankind Pharma: Large Indian pharma with presence in gynecological and hormonal categories. Comparable India-based scaled manufacturer, though broader portfolio.
• Gedeon Richter: European specialty pharma with a meaningful women's-health franchise (contraception, gynaecology). Overlapping therapeutic focus though broader portfolio and global reach.
• Bayer (Women's Health / Pharma): Diversified pharma with a major women's-health division (contraception, HRT). Competes with Naari in the same therapeutic areas but operates across many other categories.
• Cipla: Major Indian pharma with women's health and hormonal products. Comparable vertically integrated manufacturer though operations span multiple therapeutic areas.

Direct peers

• Organon & Co. Global specialty pharma whose flagship franchise is women's health, spanning contraception, fertility, and HRT. Closest direct comparable to Naari given the same therapeutic axis.
• Theramex: Women's-health-focused specialty pharma operating across contraception, HRT, and menopause. Direct competitor with overlapping women's hormone portfolio targeting similar prescribers.
• Bharat Serums and Vaccines: India-based specialty pharma with a women's health and hormone portfolio. Direct comparable given shared India-domestic specialty-pharma model and similar scale tier.
• Emcure Pharmaceuticals: Indian pharma with an established women's health business including hormonal contraceptives. Comparable vertically integrated Indian competitor in the same hormone segment.

Regional players

• HLL Lifecare: Indian public-sector contraceptives and women's health product manufacturer. Comparable in India-anchored women's hormonal products though operating model is government-owned.

Emerging players

• Mithra Pharmaceuticals: Belgian specialty women's health pharma focused on contraception and menopause. Comparable niche women's-hormone developer though earlier stage and EU-anchored.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/naari-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naari